COMMUNAUTÉ • COMMUNITY
g
Dans le cas d’antécédents familiaux
gg to strike women who have a genetic predisposition to cancer due to inherited
gene
importants, ou dès l’apparition de symp-
mutations.
la Dre Provencher conseille une consulta-
ian cancers are asymptomatic, making the detection of aggressive cancers difficult.
tômes et de lésions corporelles inhabituels,
tion afin de diminuer les risques de cancer.
Traitements et recherche
La chirurgie, la radiothérapie et la chimiothérapie sont utilisées pour traiter les can-
cers gynécologiques. Toutefois, les modali-
Owing to the mutations, the lifetime probability of these women de-
veloping endometrial cancer is 60% and 10 to 20% for ovarian cancer. Most ovarWe are witnessing the emergence of a new type of ovarian cancer. According to Dr. Pro-
vencher, it starts as a tumour with a low malignancy potential. The tumour is removed
and the problem resolved. However, it returns with a vengeance several years later. From
a tumour with a low malignancy potential, we now see plaques—deposits resembling cement—that respond poorly to traditional chemotherapy, or are totally unresponsive.
Cervical cancer is associated with the human papillomavirus (HPV) and has been the
tés thérapeutiques évoluent.
subject of public health campaigns. The HPV vaccination program has been successful, con-
les thérapies ciblées personnalisées se
be vaccinated before they have their first sexual encounter. Current cohorts demonstrate
Les chirurgies moins invasives et
concrétisent. La recherche se concentre
sur la génétique et la génomique, pour
firms Dr. Provencher, who further emphasizes that it is absolutely essential for children to
the vaccine’s effectiveness.
Heredity can play a role in cancer. BRCA1 and BRCA2 (BReast CAncer 1 and 2) gene muta-
trouver dans les tumeurs cancéreuses des
tions are chiefly associated with hereditary breast and ovarian cancer. This genetic pre-
Parp (PARPi) sont une nouvelle arme pro-
fective preventive strategies.
cibles thérapeutiques. Les inhibiteurs de
metteuse pour les patientes porteuses de
disposition is passed along from generation to generation. Hence, the development of ef-
mutation BRCA.
Prevention is Critical
ciens se mobilisent et le dialogue avec les
cancer as well as improve treatment tolerance. One can, however, reduce the chances of
Somme toute, les chercheurs et clini-
patientes est constructif. Certaines participent aussi à des protocoles de recherche.
Des résultats encourageants
A healthy lifestyle is conducive to good health. It can reduce the likelihood of developing
developing hereditary cancers by taking the course of action adopted by Angelina Jolie.
Because of the BRCA1 gene mutation, her chances of developing breast and ovarian cancer
were 80% and 11%, respectively, compared with 11% and 1.43%, respectively, for the general
population. In cases of a strong family history, or at the onset of unusual symptoms or skin
L’ouverture du Centre de recherche du
lesions, Dr. Provencher recommends a consultation in order to reduce the risks of cancer.
veau CHUM) a réuni les chercheurs travail-
Treatments and Research
facilitant la collaboration entre chercheurs
However, therapeutic modalities are evolving. Surgeries are less invasive and personalized
CHUM en octobre 2013 (phase 1 du nou-
lant autrefois à différents emplacements,
fondamentaux et cliniciens, pour le bénéfice des patients.
La Dre Provencher a dévoilé en avril 2016,
avec la Dre Helen Mackay, les résultats du
projet de recherche OV 21-PETROC, au Canadian Cancer Trials Group. Ce projet porte
Surgery, radiation therapy and chemotherapy are used to treat gynecological cancers.
targeted therapies are becoming a reality. Research is genetic- and genome-based, with a
view towards identifying therapeutic targets within cancer cells. PARP inhibitors (PARPi)
are a promising new weapon in the therapeutic armamentarium for BRCA gene mutation
carriers. In brief, researchers and clinicians are joining forces to form a constructive dialogue with patients. Some patients are also participating in research protocols.
sur la chimiothérapie intrapéritonéale (di-
Encouraging Findings
de la tumeur de l’ovaire) et sera également
brought together researchers who had previously been working at various other sites, thus
rigée directement dans l’abdomen au site
présenté au prochain congrès de l’American Society of Clinical Oncology.
Merci aux patientes, conclut la Dre
The opening of the CHUM Research Centre in October 2013 (phase 1 of the new hospital)
facilitating collaboration between basic science researchers and clinicians to the benefit of
patients.
In April 2016, Dr. Provencher, along with Dr. Helen Mackay, unveiled the findings of the
Diane Provencher. Grâce à leur ADN et leur
PETROC/OV21 trial to the Canadian Cancer Trials Group. The findings of the study, which
sui vent et sont porteuses d’espoir pour
domen at the site of the ovarian tumour), will also be presented at the next American Soci-
détermination, les recherches se pourtoutes les femmes. M
deals with intraperitoneal chemotherapy (chemotherapy delivered directly into the abety of Clinical Oncology meeting.
Dr. Provencher extends a special shout-out and thank you to patients. Thanks to their
DNA and determination, the research continues and offers a glimmer of hope to all women.
M
SUMMER 2016 MONTRÉAL enSANTÉ
23